Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Diagnosis & Disease Information
Prolonged Exportin-1 Inhibition Yields Antileukemic Activity in NPM1-Mutated Acute Myeloid Leukemia
Researchers sought to determine whether prolonged inhibition of exportin-1 would lead to antileukemic activity in an NPM1-mutated AML murine model.
Rezlidhia Now Available for Relapsed/Refractory AML With IDH1 Mutation
Rezlidhia is a small molecule inhibitor of mutated IDH1.
SLC22A3 Methylation Patterns Linked With Prognosis in Acute Myeloid Leukemia
Researchers sought to determine whether there was a relationship between methylation of the gene SLC22A3 and prognosis in different forms of AML.
Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Geriatric Assessment in Hematology Scale Predicts Treatment Tolerability in Older Patients With Hematological Malignancies
Researchers sought to assess the geriatric assessment in hematology scale in older patients diagnosed with hematological malignancies.
Triplet Deemed Effective in Newly Diagnosed AML but Not Relapsed/Refractory Disease
Combination magrolimab, azacitidine, and venetoclax appears effective in patients with newly diagnosed acute myeloid leukemia.
Triplet Appears Active in Relapsed/Refractory and Newly Diagnosed AML
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
Rezlidhia Approved for Relapsed/Refractory AML With IDH1 Mutation
Olutasidenib is a small-molecule inhibitor of mutated IDH1.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...